Skip to content

Effect of Stop Itch-Spray in fungal skin infections

Open label, Single arm, Efficacy Study of Stop Itch anti-fungal powder Spray Containing Miconazole nitrate Spray of Amrutanjan Health Care Limited, in Patients either with Cutaneous Candidiasis or Dermatophytosis (Tinea/ Ring worm).

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032235
Enrollment
45
Registered
2021-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B35- Dermatophytosis

Interventions

Intervention1: Miconazole nitrate Spray 2 %.: To use two sprays (2%) Twice daily topically, morning and night for 4 weeks. Control Intervention1: Not applicable: Not applicable

Sponsors

Amrutanjan Health Care Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in the age group between 18 to 75 years, inclusive of both male and female subjects. 2. Subjects suffering from either candidiasis(Cutaneous Candidiasis) or Dermatophytosis (Tinea/ Ring worm) (newly diagnosed cases) 3. Patients with localized superficial fungal infection confirmed by presence of fungal hyphae in KOH (potassium hydroxide) preparation of skin scrapings from over the lesion at baseline visit 4. Availability of subject for the entire study period and willing to adhere to protocol requirements as evidenced by the written ICF duly signed by the volunteer. 5.Subject who have no evidence of life life-threatening disease during screening, medical history and whose physical examination is performed within 28 days prior to commencement of the study. 6.Atopic patients, dry skin and diabetes mellitus â?? subjects with either of the above problem and willing not to use any other anti-fungal drugs other than the investigational product during the study period. 7.Subjects, who are willing to avoid sun bathing, swimming, prolonged sun exposure or artificial ultra-violet rays during the course of the study.

Exclusion criteria

Exclusion criteria: 1.Subjects with allergies to cosmetics, moisturizers, and whitening/bleaching agents. 2.Subjects who has sunburned, chapped, or irritated skin or open wounds on test sites. 3.Subjects who are not willing to discontinue any other personal care products containing whitening/bleaching properties during study period. 4.History of skin cancer or treatment for any type of cancer within the last 2 years. 5.Subjects who are with underlying immunosuppressive state. 6.Subjects who applied any other topical agent over the lesions prior to baseline visit. 7.Pregnant women or nursing mothers.

Design outcomes

Primary

MeasureTime frame
1. Mycological & Clinical Cure : An assessment will be made based on the presence or absence of fungal elements in KOH preparation and mycological cure will be done at the end of the treatment and clinical improvement if evident in between (Time frame: 1-4 weeks). 2. Onset of action : (relief of itching: (30 sec, 1 min, 2 min, 5 min, 10 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 12 hrs and 24 hrs). 3. Onset of action: (relief from scaling & skin irritation if any) : (Time frame : day1-day 28) Timepoint: Week 1,2,3 and 4

Secondary

MeasureTime frame
1. Additionally, during each visit (week1, 2 and 3), subjects will be enquired regarding the symptomatic change from the initial stage and reduction in itching and scaling (using VAS scores) will be captured in the CRF. 2. Patient compliance and Quality of life pre and post treatment will be enquired. Timepoint: Week 1,2,3 and 4

Countries

India

Contacts

Public ContactDr Ramesh Kannan

KI3, CRO

srkguruvarshan@gmail.com7708925866

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026